Targeting the Peroxisome Proliferator-Activated Receptor-gamma to Counter the Inflammatory Milieu in Obesity.
10.4093/dmj.2013.37.6.395
- Author:
Cesar CORZO
1
;
Patrick R GRIFFIN
Author Information
1. Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL, USA. pgriffin@scripps.edu
- Publication Type:Review
- Keywords:
Diabetes;
Hypoglycemic agents;
Metabolic disorders;
Metabolic syndrome;
PPAR gamma;
Protein processing, post-translational;
Receptors, cytoplasmic and nuclear;
Review;
Synthetic ligands;
Thiazolidinediones
- MeSH:
Adipokines;
Adipose Tissue;
Hypoglycemic Agents;
Immune System;
Inflammation;
Insulin Resistance;
Models, Animal;
Obesity*;
Peroxisomes*;
PPAR gamma;
Protein Processing, Post-Translational;
Receptors, Cytoplasmic and Nuclear;
Thiazolidinediones;
Triglycerides
- From:Diabetes & Metabolism Journal
2013;37(6):395-403
- CountryRepublic of Korea
- Language:English
-
Abstract:
Adipose tissue, which was once viewed as a simple organ for storage of triglycerides, is now considered an important endocrine organ. Abnormal adipose tissue mass is associated with defects in endocrine and metabolic functions which are the underlying causes of the metabolic syndrome. Many adipokines, hormones secreted by adipose tissue, regulate cells from the immune system. Interestingly, most of these adipokines are proinflammatory mediators, which increase dramatically in the obese state and are believed to be involved in the pathogenesis of insulin resistance. Drugs that target peroxisome proliferator-activated receptor-gamma have been shown to possess anti-inflammatory effects in animal models of diabetes. These findings, and the link between inflammation and the metabolic syndrome, will be reviewed here.
